About the Thrive-IVF Research Study
The Thrive-IVF Research Study (NT-03) is a randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy, safety and tolerability of NT100 in approximately 150 women 21-38 years of age who have had repeated (three or more) IVF failures despite having good-quality embryos. Study participants will be randomized to receive NT100 (low or high dose) or placebo. The study will be conducted at approximately 15-20 clinical sites in major metropolitan areas across the U.S. Visit http://www.thriveivf.com or www.clinicaltrials.gov for more information.
Houston Fertility Institute
We at Houston Fertility Institute (HFI) are dedicated to helping infertile couples realize their dream of conceiving a child. Couples that have been trying to conceive for months, or even years, can rest assured that we have the training and experience to help them overcome infertility. As leaders in the field of reproductive medicine, our doctors offer the most advanced treatments available in a warm, friendly atmosphere. Because we understand that each of our couples is facing their own unique issues and challenges, we strive to provide compassionate care that is customized to their needs and goals.
About Nora Therapeutics, Inc.
Nora Therapeutics, Inc., is a specialty biopharmaceutical company focused on developing therapeutics to address unmet clinical needs in reproductive medicine. Nora's lead compound, NT100, is being specifi
|SOURCE Nora Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved